HENLIUS: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2024
HENLIUS: VOLUNTARY ANNOUNCEMENT -AN INTERNATIONAL MULTI-CENTER PHASE 3 CLINICAL STUDY OFPERTUZUMAB BIOSIMILAR HLX11 (RECOMBINANT ANTI-HER2DOMAIN II HUMANIZED MONOCLONAL ANTIBODY INJECTION) FORTHE NEOADJUVANT THERAPY OF HER2-POSITIVE, HR-NEGATIVEEARLY OR LOCALLY ADV
HENLIUS: VOLUNTARY ANNOUNCEMENT - SERPLULIMAB INJECTION (CHINESE TRADE NAME: HANSIZHUANG)RECEIVED POSITIVE OPINION FROM THE COMMITTEE FORMEDICINAL PRODUCTS FOR HUMAN USE (CHMP)OF THE EUROPEAN MEDICINES AGENCY (EMA)
HENLIUS: Disclosure of Dealings under Rule 22 of the Takeovers Code
HENLIUS: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2024
HENLIUS: Disclosure of Dealings under Rule 22 of the Takeovers Code
HENLIUS: Disclosure of Dealings under Rule 22 of the Takeovers Code
HENLIUS: VOLUNTARY ANNOUNCEMENT - APPLICATION FOR THE CLINICAL TRIAL OFPEMBROLIZUMAB BIOSIMILAR HLX17 (RECOMBINANTHUMANISED ANTI-PD-1 MONOCLONAL ANTIBODY INJECTION)APPROVED BY NATIONAL MEDICAL PRODUCTSADMINISTRATION
HENLIUS: CHANGE OF JOINT COMPANY SECRETARY,PROCESS AGENT AND AUTHORISED REPRESENTATIVE
HENLIUS: VOLUNTARY ANNOUNCEMENT -HLX02 (TRASTUZUMAB FOR INJECTION, PRODUCT NAME IN CANADA:ADHEROZA) FOR THE TREATMENT OF EARLY BREAST CANCER,METASTATIC BREAST CANCER AND METASTATIC GASTRIC CANCERAPPROVED BY THE HEALTH CANADA
HENLIUS: VOLUNTARY ANNOUNCEMENT -THE FIRST PATIENT HAS BEEN DOSED IN A PHASE 2 CLINICAL TRIALOF HLX53 (ANTI-TIGIT FC FUSION PROTEIN) IN COMBINATIONWITH HANSIZHUANG (SERPLULIMAB INJECTION) AND HANBEITAI(BEVACIZUMAB INJECTION) FOR THE FIRST-LINE TREATMENTOF LOCALLY A
HENLIUS: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2024
HENLIUS: Disclosure of Dealings under Rule 22 of the Takeovers Code
HENLIUS: Disclosure of Dealings under Rule 22 of the Takeovers Code
HENLIUS: Disclosure of Dealings under Rule 22 of the Takeovers Code
HENLIUS: Disclosure of Dealings under Rule 22 of the Takeovers Code
HENLIUS: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2024
HENLIUS: VOLUNTARY ANNOUNCEMENT - HANSIZHUANG (SERPLULIMAB INJECTION) IN COMBINATIONWITH BEVACIZUMAB INJECTION AND CHEMOTHERAPY HAS BEENPERMITTED TO COMMENCE AN INTERNATIONAL MULTICENTREPHASE 3 CLINICAL TRIAL FOR THE FIRST-LINE TREATMENT OFMETASTATIC COLORECTAL CAN
HENLIUS: APPOINTMENT OF CHIEF FINANCIAL OFFICER
HENLIUS: VOLUNTARY ANNOUNCEMEN - THE PHASE 1 CLINICAL STUDY OF A BIOSIMILAR OF DARATUMUMABHLX15 (RECOMBINANT ANTI-CD38 HUMAN MONOCLONAL ANTIBODYINJECTION) SUCCESSFULLY COMPLETED
No Data
No Data